Molecular genetics
DNA was extracted from the frozen brain tissue and the PRNP coding region analysed as previously described 7, 8 .
Prevalence, clinical and histopathological evaluations
All sporadic 129 MM cases diagnosed by histopathological or histopathological and WB examinations at the NPDPSC during the 2005-2014 period were selected. Cases of VPSPr were excluded; cases of sCJDMM1-2 (we observed no sFI1-2 cases) were attributed to the sCJDMM1 or sCJDMM2 categories according to the predominant phenotype 9 . Prevalences of sFI and sCJDMM2 are expressed as percentage of these two conditions with respect to the total number of sporadic 129MM cases.
Retrospective chart review was carried out for all subjects paying particular attention to the clinical presentation of the disease.
Histology and immunohistochemistry were carried out as previously described 10 . Brain sections from frontal, temporal, parietal and occipital neocortices, hippocampus, neo-striatum, thalamus and cerebellar hemisphere were assessed for presence and severity of spongiform degeneration, neuronal loss and astrogliosis. Immunohistochemistry was performed with mAb 3F4 to determine the presence and pattern of PrP 
Methanol precipitation
Samples were mixed 1:5 with pre-chilled methanol, vortexed and incubated at -20°C for at least 2 hours before centrifugation at 16,000 x g for 30 min at 4°C. The pellets were resuspended in buffer.
Methanol-chloroform precipitation
NaPTA pellets were incubated with 4-fold volumes of methanol-chloroform (2:1) solution and centrifuged at 16,000 x g for 30 min at 4°C; they were then resuspended in buffer.
Deglycosylation by PNGase F
PNGase F was used as recommended by the manufacturer. Briefly, NaPTA or methanol pellets were resuspended in 1X Glycoprotein Denaturing Buffer and incubated at 100°C for 10 min.
After addition of Nonidet P-40 and G7 Reaction Buffer, PNGase F was added; the mixture was incubated overnight at 37°C. PNGase F was then heat-inactivated at 75°C for 10 min.
Immunoprecipitation with 8B4
According to manufacturer's instructions, Dynabeads M-270 Epoxy (5 mg, ~3.35 x 10 8 beads)
were conjugated to 100 µg of purified mAb 8B4 using the Dynabeads Antibody Coupling Kit reaching a final concentration of 10 mg 8B4-coupled beads/ml. Prior to IP, cleared homogenates from sCJDMM2 and sFI cases were subjected to NaPTA and methanol-chloroform precipitations; the final pellets were resuspended in 15 µl of 8 M GdnHCl solution, sonicated and heated at 80°C for 5 min. These samples were then diluted to 100 µl with LB 100 pH 8.0 containing protease inhibitors (1 mM PMSF and 5μg/ml aprotinin and leupeptin), and were incubated with ~2.35 x 10 7 8B4-coupled beads and a solution containing 3% Tween 20, 3%
Nonidet P-40 in 1X PBS pH 7.4, to reach a reaction volume of 1 ml. The tubes were incubated with tilting and rotation overnight at 4°C, and placed on a magnet, allowing the beads to pellet completely; they were then washed nine times with a solution containing 2% Tween 20, 2% Nonidet P-40 in 1X PBS pH 7.4. Then, a final wash with 1X PBS pH 7.4 was performed. In cases of PK treatment, the beads were resuspended in 30 µl of LB 100 pH 8.0 and incubated with PK (5 U/ml) for 1 hour at 37˚C constantly mixing; the reaction was blocked with 3 mM PMSF prior to the addition of 2X sample buffer and elution. Two alternative protocols were used for antigen elution of PK-untreated samples: i) incubation of the beads in 1X sample buffer (1.05% SDS, 13.2% glycerol, 0.005% bromophenol blue, 2.5% β -mercaptoethanol, 32.9 mM Tris-HCl, pH 6.8) and heating at 96°C for 6 min (PK-treated samples were directly boiled after addition of 2X sample buffer); ii) incubation of the beads in urea elution buffer (8 M urea, 2% CHAPS, 20 mM Tris pH 8.0) for 1 hour at room temperature with constant mixing. In both cases the beads were then separated from the eluate using a magnet. The eluates in 1X sample buffer were boiled at 100°C for 10 min whereas the samples in urea elution buffer were first reduced with 5 mM TBP, then alkylated with 20 mM iodoacetamide and then subjected to the ReadyPrep 2-D Cleanup Kit which reduces detergents, salts and lipids. The pellets were resuspended in rehydration buffer (7 M urea, 2 M thiourea, 1% DTT, 1% CHAPS, 1% Triton X-100, 0.2 % BioLyte 3/10 ampholyte) for isoelectric focusing (IEF) applications, but where indicated they were resuspended in either 1X sample buffer or 1X Glycoprotein Denaturing Buffer.
Antibody co-elution
To test whether covalent bonding between 8B4 and Dynabeads M-270 Epoxy formed during coupling prevented antibody leakage during the elution, sCJDMM2 and sFI were subjected to IP-8B4; after the last wash with 1X PBS pH 7.4, the beads were separated in two tubes and eluted either in 1X sample buffer or urea elution buffer. For samples eluted in urea elution buffer, ReadyPrep 2-D Cleanup Kit was used and the resulting pellets were resuspended in 1X sample buffer and boiled at 100°C for 10 min. The samples were then subjected to 1-D electrophoresis and immunoblot with i) mAb 3F4; ii) rabbit anti-N-terminal antiserum anti-N; iii) rabbit anti-Cterminal antiserum 2301; iv) goat anti-mouse IgG (Fc) HRP conjugate (that was also used as secondary Ab for 3F4 detection); and v) donkey anti-rabbit IgG HRP-linked whole antibody (also used as secondary Ab for anti-N and 2301 detection).
Immunoprecipitation with OCD4
IP with OCD4 was performed as described 6 , with minor modifications. OCD4-coupled beads were incubated with similar amounts of PrP in each sample. Samples referred to as fractions 4-8 and 17-21 were obtained by combining the contents of the selected fractions obtained with SE experiments from N=2 cases of sCJDMM2 and sFI. S1 and S2 samples (see "Preparation of detergent insoluble fraction") were obtained from a case unaffected by neurological disease.
Elution was performed by heating the beads at 95°C for 5 min in SDS sample buffer (3% SDS, 2 mM EDTA, 10% glycerol, 50 mM Tris-HCl, pH 6.8).
1-D electrophoresis and immunoblot
Proteins were separated with 15% Criterion Tris-HCl polyacrylamide precast gels and blotted into Immobilon-FL PVDF membranes for 2 hours at 60V, which were then rinsed with 1X PBS and blocked with Odyssey Blocking Buffer for 1 hour at room temperature before being probed overnight, at 4°C. The primary antibodies were diluted in Odyssey Blocking Buffer with 0.1% Tween 20 as follows: 3F4 (1:40,000 except for SE, SV and CSSA in which it was used at a dilution of 1:4,000); anti-N (1: 2,000); 2301 (1:3,000) and 8B4 (1:10,000, stock 2 mg/ml). After four washes with PBS-T (1X PBS with 0.1% Tween 20), the membranes were incubated for 1 hour with IRDye 800CW goat anti-mouse IgG (1:15,000) or IRDye 680RD goat anti-rabbit IgG 
2-D electrophoresis and immunoblot
The first dimension (isoelectric focusing) of 2-D PAGE was performed as previously described with minor modifications 11 . Briefly, 11 cm Ready-Strip IPG Strips pH 3-10 were rehydrated for 15 hours with the samples and subjected to isoelectric focusing with PROTEAN IEF Cell (BioRad), for ∼ 40,000 Vh. The IPG Strips were then equilibrated in SDS and reducing/alkylating agents in a two-step process by the addition of 130 mM DTT and 135 mM iodoacetamide, respectively, to the equilibration buffer (6M urea, 2% SDS, 20% glycerol, 0.375 M Tris-HCl pH 8.8), prior to running the second dimension gels. Criterion Tris-HCl polyacrylamide precast gels (8-16%) were used. Proteins were transferred into Immobilon-P PVDF membranes for 2 hours at 60 V; the membranes were then blocked with 5% non-fat dry milk in TBS-T for 1 hour at room temperature before being incubated overnight, at 4°C, with mAb 3F4 (1:40,000). After five washes with TBS-T, the membranes were incubated with goat anti-mouse IgG (Fc)-HRP conjugate (1:5,000) for 1 h at room temperature, washed again and developed by enhanced chemiluminesce reaction using ECL and ECL plus reagents, as recommended by the manufacturer. The signal was captured on Kodak MR and XAR films.
Sodium phosphotungstate precipitation
After addition of a protease inhibitors cocktail (final concentration 1mM PMSF and 5μg/ml aprotinin and leupeptin), the 5% homogenates were incubated with a solution 10% (w/v) NaPTA/85 mM MgCl 2 (final concentration 0.32% NaPTA/2.72 mM MgCl 2 ) for at least 1h at 37˚C while shaking. A supernatant and a pellet were recovered by 14,000 x g centrifugation for 30 min at 20˚C. The supernatants were stored at -80˚C and the pellets were washed in 1X D-PBS pH 7.4 before their resuspension in buffer. For 2-D PAGE, pellets were precipitated by methanol-chloroform.
Preparation of detergent insoluble fraction
BH (20% w/v) in 1X Dulbecco's PBS pH 7.4 were mixed with an equal volume of 2X LB100 pH 8 (200 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 20 mM EDTA, 200 mM TrisHCl, pH 8.0), incubated at least 10 min at 4˚C and centrifuged at 1,000 x g for 10 min at 4°C.
The supernatant obtained, identified as S1, was then ultracentrifuged at 100,000 x g for 1 h at 4°C in a SW55 rotor (Beckman) to generate a supernatant (S2) and pellet (P2) for each sample 12 .
The P2 were resuspended in cold LB 100 pH 8.0; the S2 were stored in -80°C.
Preparation of detergent insoluble fraction under stringent conditions
Stringent conditions were used to maximize PrP C solubility and to guarantee that in the resulting P2 the level of PrP C contamination was less than 1% of the total PrP contained in the BH.
Briefly, BH (20% w/v) in 1X TEND (65 mM NaCl, 0.5 mM EDTA, 10 mM Tris pH 8.0) were mixed with an equal volume of a solution 20% sarkosyl NL in 1X TEND containing a protease inhibitor cocktail, and incubated at 4˚C for 30 min with frequent mixing. S1, obtained by centrifuging the samples at 18,000 rcf for 25 min at 4°C, were subsequently centrifuged at 100,000 x g for 2 h at 4°C in a SW55 rotor to generate S2 and P2 obtained under stringent conditions 13 , with minor modifications. The P2 were either resuspended in LB 100 pH 8.0 or 1% sarkosyl NL TNE pH 7.2 (150 mM NaCl, 5 mM EDTA, 25 mM Tris pH 7.5).
Sedimentation equilibrium
SE was performed with the intent of separating the particles based on their individual densities 14 . P2 fractions containing comparable PrP Sc amounts (determined by immunoblot with 3F4) or originating from identical volumes of BH (brain equivalents) were loaded on top of step sucrose gradients (10% to 60%), prepared in 1% sarkosyl NL TNE pH 7.2. The P2 samples [either PK-treated (PK 10 U/ml) or -untreated] were subjected to ultracentrifugation at 200,000 x g for 19 hours at 4°C in a SW55 rotor (Beckman). For each sample, 21 fractions were collected from the top of the tube, the content of which was concentrated by methanol precipitation and resuspended in LB 100 pH 8.0 by sonication in ice. SE generated using insoluble fractions prepared under stringent conditions were indicated as stringent conditions SE. The samples were then either treated with PK (as separate fractions of identical volume or as a combination of selected fractions, when indicated) or directly mixed with an equal amount of 2X sample buffer and boiled at 100°C for 10 min. Identical volumes of each fraction were then subjected to immunoblot with 3F4 and densitometry analysis. The signal in each fraction was normalized as percent of the total and plotted as mean ± SD for each group. Graph lines identified the sedimentation curves for each sample group. Fraction 21 was excluded from the glycoform ratio analysis due to smearing of bands. values for each group ± standard error were determined and plotted. Quantitative analysis of glycoform ratios in the peaks of sCJDMM2 and sFI shows similar profiles in both diseases that also resemble those of previously unfractionated resPrP
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